SCHEMBL2193786

SCHEMBL2193786

Nc1ccc(Oc2cccc(C(=O)Nc3cccc(C(F)(F)F)c3)c2)cc1

nearest known ligand 0.67

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PTGS1 P23219 4/20 0.67
MAPT P10636 3/20 0.66
KCNK3 O14649 2/20 0.58
RXFP1 Q9HBX9 2/20 0.58
P2RX1 P51575 1/20 0.57
LMNA P02545 1/20 0.57
CDK8 P49336 2/20 0.57
KDR P35968 2/20 0.56
MEN1 O00255 3/20 0.56
KMT2A Q03164 3/20 0.56
ALDH1A1 P00352 1/20 0.56
GAA P10253 1/20 0.56
ALOX12 P18054 1/20 0.56
CCR6 P51684 1/20 0.56
HTT P42858 1/20 0.56
RAB9A P51151 1/20 0.56
BTK Q06187 1/20 0.55
KCNK9 Q9NPC2 1/20 0.55
CDK7 P50613 1/20 0.54
CDK6 Q00534 1/20 0.54

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22225314 0.95 PTGS1 (0.71) PTGS1MAPTKCNK3RXFP1P2RX1
SCHEMBL2191824 0.89 PTGS1 (0.69) PTGS1KDRRAB9A
SCHEMBL18585854 0.87 CDK8 (0.73) MAPTLMNACDK8KDRMEN1
SCHEMBL30544816 0.87 CDK8 (0.73) MAPTLMNACDK8KDRMEN1
SCHEMBL2192224 0.84 FFAR1 (0.74) MAPTKCNK3RXFP1P2RX1LMNA
SCHEMBL8148883 0.84 KCNK3 (0.69) MAPTKCNK3RXFP1P2RX1LMNA
SCHEMBL11307930 0.84 PTGS1 (0.76) PTGS1MAPTKCNK3RXFP1P2RX1
SCHEMBL4463935 0.82 PTGS1 (0.89) PTGS1MAPTKCNK3RXFP1P2RX1
SCHEMBL826565 0.82 PTGS1 (0.57) PTGS1MAPTKCNK3RXFP1LMNA
SCHEMBL2196842 0.82 ALDH1A1 (0.55) PTGS1MAPTKCNK3RXFP1LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2181987-B9 2-Carbonylaminobenzothiazoles and their use for the prophylaxis and treatment of cancer TAKEDA PHARMACEUTICAL (JP) 2014-09-03 EP disclosed
EP-2181987-B1 2-Carbonylaminobenzothiazoles and their use for the prophylaxis and treatment of cancer TAKEDA PHARMACEUTICAL (JP) 2014-03-05 EP disclosed
US-8324395-B2 Heterocyclic compound and use thereof TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2012-12-04 US disclosed
US-20110172245-A1 HETEROCYCLIC COMPOUND AND USE THEREOF TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2011-07-14 US disclosed
EP-2181987-A1 HETEROCYCLIC COMPOUND AND USE THEREOF Takeda Pharmaceutical Company Limited (JP) 2010-05-05 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110172245-A1 HETEROCYCLIC COMPOUND AND USE THEREOF BRAF, NRAS, RAF1 PTGS1 2828/4885MAPT 3535/4885KCNK3 3361/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.